普鲁卡因胺治疗期间的抗核抗体与药物乙酰化
Antinuclear antibodies during procainamide treatment and drug acetylation.
作者信息
Davies D M, Beedie M A, Rawlins M D
出版信息
Br Med J. 1975 Sep 20;3(5985):682-4. doi: 10.1136/bmj.3.5985.682.
Acetylator capacity was determined in two groups of patients who had received procainamide for more than three months. In seven patients antinuclear antibodies (A.N.A.) were detected during treatment, and these changes disappeared (in six patients) or were less pronounced (one patient) after withdrawal of the drug. These patients tended to have faster acetylation rates, and five were phenotypically "rapid" acetylators. Five patients who did not develop A.N.A. during treatment had less rapid (P less than 0.05) rates of acetylation, and four were "slow" acetylators. We suggest that the immunological changes which may occur during procainamide treatment may be associated with the acetylated metabolite of procainamide rather than the parent compound and that it might be possible to identify patients at risk.
对两组接受普鲁卡因胺治疗超过三个月的患者进行了乙酰化能力测定。在七名患者的治疗过程中检测到了抗核抗体（A.N.A.），停药后这些变化消失了（六名患者）或变得不那么明显（一名患者）。这些患者往往具有较快的乙酰化速率，其中五名在表型上为“快速”乙酰化者。五名在治疗期间未出现抗核抗体的患者乙酰化速率较慢（P<0.05），其中四名是“缓慢”乙酰化者。我们认为，普鲁卡因胺治疗期间可能发生的免疫变化可能与普鲁卡因胺的乙酰化代谢产物有关，而非与母体化合物有关，并且有可能识别出有风险的患者。
Zotero 插件